Celyad announced the injection of the first patient in the Phase 1 alloSHRINK trial evaluating the company’s non-gene edited allogeneic CAR-T therapy, CYAD-101, administered concurrently with FOLFOX chemotherapy in the treatment of patients with unresectable metastatic colorectal cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.